Preparing for phase I IND for paradigm shifting alpha radiotherapy [211AT]PTT to treat ovarian cancer

Active Grant Awarded

Award ID
R44CA310342
Recipient
Awarding agency
Obligated
$1,174,824

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 9% complete
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Trevarx Biomedical, Inc. a grant of $1.174824 million on September 17, 2026, under Assistance Listing 93.395, Cancer Treatment Research. Grant R44CA310342 is an SBIR Direct to Phase 2 project that funds preparation of an IND for a Phase 1 trial of [211At]PTT, a PARP-1 targeted alpha radiotherapy agent for ovarian cancer.

The project will generate IND-enabling data for the Phase 1 trial to assess human toxicity and define the maximum tolerated dose, confirm the fractionated dosing scheme, provide an early indication of efficacy, and test [18F]FTT as a companion diagnostic for [211At]PTT therapy. Rat and mouse models will establish first-in-human dosimetry and dosing regimen and determine human safety based on toxicity and biodistribution research, as the FDA requires for therapeutic radiopharmaceuticals. Successful completion enables a first-in-human Phase 1 trial of the agent.

The period of performance ends August 31, 2028, and the place of performance is Philadelphia, PA 19104.

Description

Abstract
Ovarian cancer (OVCA) is the leading cause of gynecologic cancer death. Poly (ADP-RIBOSE) polymerase 1 inhibitors (PARPI) therapy is the standard of care for OVCA but 70% of patients relapse within five years due to HRD reversion resistance mechanisms. [211AT]parthanatine ([211AT]PTT), a parp-1 targeted alpha agent, deposits energy directly at the DNA, creating lethal double-stranded break while sparing normal surrounding tissues. 211AT is a highly promising halide radioisotope for a-radiotherapy when paired with our small molecule PARPI analog targeting subcellular DNA with significant advantages over ~-emitters and other a-emitters. Our companion imaging agent, [18F]fluorthanatrace ([18F]FTT) binds to the same target as [211AT]PTT, enabling patient selection and treatment monitoring. Together, [18F]FTT and [211AT]PTT form a novel theranostic platform that addresses a critical unmet need in OVCA. Preclinical studies at penn demonstrate that [211AT]PTT is potent across ovarian cancer models and independent of PARPI sensitivity, with unprecedented tumor response and marrow recovery within four weeks under a fractionated dosing scheme. This sbir direct to phase 2 project will generate the IND enabling data for a phase 1 trial of [211AT]PTT that will 1) assess human toxicity and define the maximum tolerated dose, 2) confirm the fractionated dosing scheme, 3) provide an early indication of efficacy and 4) test the use of [18F]FTT as a companion diagnostic for [211AT]PTT therapy. RAT and mice models in this grant are needed to establish first in human dosimetry and dosing regimen as well as determine human safety based on toxicity and biodistribution research as required by the FDA for therapeutic radiopharmaceuticals. Successful completion will enable a firstin- human phase 1 trial of a DNA TAT in OVCA with broad potential across cancers with measurable parp-1 update including prostate, breast, pediatric neuroblastoma and small cell lung cancer.

Quick answers

Who received award R44CA310342?

R44CA310342 was awarded to Trevarx Biomedical, Inc. by National Cancer Institute (National Institutes of Health) on September 17, 2026.

How much is award R44CA310342 worth?

$1,174,824 has been obligated on R44CA310342.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award